HPV6b virus like particles are potent immunogens without adjuvant in man

Vaccine

Volumn 18, Issue 11-12, 2000, Pages 1051-1058

  Zhang, Li Fang ^a   Zhou, Jian ^b   Chen, Shao ^a   Cai, Lian Lian ^a   Bao, Qi Yu ^a   Zheng, Fei Yun ^a   Lu, Jie Qiang ^a   Padmanabha, Jagadish ^b   Hengst, Kylie ^b   Malcolm, Karen ^b   Frazer, Ian H ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Papillomavirus; Vaccines; Virus like particles

Indexed keywords

CAPSID PROTEIN; VIRUS VACCINE;

ADULT; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN BIOPSY; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID; CONDYLOMATA ACUMINATA; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; MIDDLE AGED; PAPILLOMAVIRIDAE; VIRAL VACCINES;

EID: 0344771067     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00351-5     Document Type: Article

References (44)

1. Shah K.V. Human papillomaviruses and anogenital cancers [editorial; comment]. N. Engl. J. Med. 337:1997;1386-1388.
2. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102:1997;3-8.
3. Beutner K.R., Ferenczy A. Therapeutic approaches to genital warts. Am. J. Med. 102:1997;28-37.
4. Barrasso R. Treatment of genital warts: an overview. J. Obstet. Gynecol. 18:1998;S70-S71.
5. Bouwes B.J., Berkhout R.J. HPV infections and immunosuppression. Clin. Dermatol. 15:1997;427-437.
6. Frazer I.H., McMillan N.A. Papillomatosis and condylomata acuminata. Stuart-Harris R., Penny R.W. Clinical applications of the interferons. 1997;79-91 Chapman and Hall Medical, London.
7. Beutner K.R., Tyring S.K., Trofatter K.F. Jr, Douglas J.M. Jr, Spruance S., Owens M.L., Fox T.L., Hougham A.J., Schmitt K.A. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 42:1998;789-794.
8. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 89:1992;12180-12184.
9. Rose R.C., Bonnez W., Reichman R.C., Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J. Virol. 67:1993;1936-1944.
10. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991;251-257.
11. Hines J.F., Ghim S.J., Jenson A.B. Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Curr. Opin. Infect. Dis. 11:1998;57-61.
12. Hagensee M.E. Progress in the development of HPV vaccines. Infect. Med. 14:1997;555-556.
13. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J.T., Lowy D.R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:1995;3959-3963.
14. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44.
15. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA. 92:1995;11553-11557.
16. Qi Y.M., Peng S.W., Hengst K., Evander M., Park D.S., Zhou J., Frazer I.H. Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein. Virology. 216:1996;35-45.
17. Park D.S., Selvey L.A., Kelsall S.R., Frazer I.H. Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J. Virol. Methods. 45:1993;303-318.
18. Pettit A.R., Quinn C., MacDonald K.P., Cavanagh L.L., Thomas G., Townsend W., Handel M., Thomas R. Nuclear localization of RelB is associated with effective antigen-presenting cell function. J. Immunol. 159:1997;3681-3691.
19. Christensen N.D., Reed C.A., Cladel N.M., Han R., Kreider J.W. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70:1996;960-965.
20. Price A.A., Cumberbatch M., Kimber I., Ager A. Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J. Exp. Med. 186:1997;1725-1735.
21. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., McMillan N.A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:1997;2449-2456.
22. Rose R.C., Bonnez W., Da Rin C., McCance D.J., Reichman R.C. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J. Gen. Virol. 75:1994;2445-2449.
23. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.-J., Schlegel R., Jenson A.B., Kreider J.W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 205:1994;329-335.
24. Frazer I.H. Immunology of papillomavirus infection. Curr. Opin. Immunol. 8:1996;484-491.
25. Greenstone H.L., Nieland J.D., De Visser K.E., De Bruijn M.L., Kirnbauer R., Roden R.B., Lowy D.R., Kast W.M., Schiller J.T. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA. 95:1998;1800-1805.
26. Peng S.W., Frazer I.H., Fernando G.J., Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology. 240:1998;147-157.
27. Beutner K.R., Spruance S.L., Hougham A.J., Fox T.L., Owens M.L., Douglas J.M. Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J. Am. Acad. Dermatol. 38:1998;230-239.
28. Edwards L., Ferenczy A., Eron L., Baker D., Owens M.L., Fox T.L., Hougham A.J., Schmitt K.A. HPV SG. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. 134:1998;25-30.
29. Schonfeld A., Nitke S., Schattner A., Wallach D., Crespi M., Hahn T., Levavi H., Yarden O., Shoham J., Doerner T. Intramuscular human interferon-beta injections in treatment of condylomata acuminata. Lancet. 1:1984;1038-1042.
30. Gentile G., Formelli G., Busacchi P., Pelusi G. Systemic interferon therapy for female florid genital condylomata. Clin. Exp. Obstet. Gynaecol. 21:1994;198-202.
31. Syed T.A., Lundin S., Cheema K.M., Kahlon B.M.M., Cheema R., Ahmad S.A., Ahmad M. Human leucocyte interferon-α in cream, for the treatment of genital warts in asian women: a placebo-controlled, double-blind study. Clin. Invest. 72:1994;870-873.
32. Syed T.A., Khayyami M., Kriz D., Svanberg K., Kahlon R.C., Ahmad S.A. Management of genital warts in women with human leukocyte interferon-alpha vs. podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J. Mol. Med. 73:1995;255-258.
33. Welander C.E., Homesley H.D., Smiles K.A., Peets E.A. Intralesional interferon alfa-2b for the treatment of genital warts. Am. J. Obstet. Gynecol. 162:1990;348-354.
34. Eron L.J., Judson F., Tucker S., Mills J., Murphy K., Hickey M., Flannigan S., Hien N., Katz H.I., Gottlieb A., Adams K., Tanner D., Taylor E., Prawer S., Peets E., Rogers M., Goldman M., Burton P. Interferon therapy for condylomata acuminata. N. Engl. J. Med. 315:1986;1059-1064.
35. Friedman-Kien A.E., Eron L.J., Conant M., Growdon W., Badiak H., Bradstreet P.W., Fedorczyk D., Trout J.R., Plasse T.F. Natural interferon alfa for treatment of condylomata acuminata. JAMA. 259:1988;533-538.
36. Olmos L., Vilata J., Rodriguez P.A., Lloret A., Ojeda A., Calderon M.D. Double-blind, randomized clinical trial on the effect of interferon-beta in the treatment of condylomata acuminata. Int. J. STD. AIDS. 5:1994;182-185.
37. Recurrent condylomata acuminata treated with recombinant interferon alpha-2a. Acta Derm. Venereol. (Stockh.). 73:1993;223-226.
38. Bornstein J., Pascal B., Zarfati D., Goldshmid N., Abramovici H. Recombinant human interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy. Int. J. STD. AIDS. 8:1997;614-621.
39. Thompson H.S.G., Davies M.L., Holding F.P., Fallon R.E., Mann A.E., O'Neill T., St Clair Roberts J. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine. 17:1999;40-49.
40. Lacey C.J.N., Thompson H.S.G., Monteiro E.F., O'Neill T., Davies M.L., Holding F.P., Fallon R.E., Roberts J.S.C. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. 179:1999;612-618.
41. De Bruijn H.W., Greenstone H.L., Vermeulen H., Melief C.J., Lowy D.R., Schiller J.T., Kast W.M. L1 specific protection from tumor challenge elicited by HPV16 virus like particles. Virology. 250:1998;371-376.
42. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb. Pathog. 22:1997;219-225.
43. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.K., Kuypers J., Kiviat N., Galloway D.A. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174:1996;927-936.
44. Müller M., Zhou J.A., Reed T.D., Rittmüller C., Burger A., Gabelsberger J., Braspenning J., Gissmann L. Chimeric papillomavirus-like particles. Virology. 234:1997;93-111.